Indaptus Therapeutics Inc INDP

$2.30 -0.55 (-19.30%)

Valuation

Market cap
438,366,000
Revenue TTM
$0
Net income TTM
$-20,850,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
641,097
Avg volume
996,566
Day's range
$2.26 – $2.91
Shares out
133,242,000
Stochastic %K
3%
Beta
1.17
Analysts
Strong Buy
Price target
$10.00

Price

Company profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency...

Show more

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 427 2727
Website
https://indaptusrx.com
Address
Three Columbus Circle, 15th Floor, New York, United States

Latest news

Stocktwits

flychicken1991 Sep 30, 3:25 PM
$INDP Indaptus Therapeutics Extends $24 Million Private Placement Closing to Oct. 16 - TradingView. Impact: Negative (78%). INDP's stock faces downward valuation pressure because the expected financing proceeds remain contingent for longer, increasing uncertainty about access to capital; the extension itself does not establish additional dilution. Source and what to watch next: https://nimpact.tech/newsimpact/news/bf523afd52f062e5/indp-indaptus-therapeutics-extends-24-million-private-placement-closing?utm_source=stocktwits&utm_medium=story_url
0 replies
focafoca99 Sep 30, 1:17 PM
$INDP closed a $24M private placement stock purchase agreement, extending its funding deadline to Oct 16.
0 replies
TwongStocks Sep 30, 1:09 PM
$INDP The closing date of the private placement from earlier in Sept has been extended to Oct 16. https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226045040/form8-k.htm Details of the private placement 👇
0 replies
MarketDegenerate Sep 29, 12:57 AM
$INDP — September has been wild for Indaptus. The company raised roughly $24M and is exploring a new direction involving neurotechnology for sleep-related conditions after stopping enrollment in its Decoy20 cancer program. Definitely a major strategy shift, and now the question is how management puts that new capital to work.
0 replies
TheJackofAll Sep 26, 6:31 PM
$INDP $AEMD Why I believe everyone should be bullish on Solar. Solar is the future. Solar can be deployed quickly, scales massively, and continues getting cheaper. -FTCI one of the beaten down Solar gems, look below why it's so undervalued!../
0 replies
robanbieber Sep 23, 4:41 PM
$INDP oh ffs just stop the manipulation and do the offering already...
1 replies
daybaron Sep 22, 8:09 PM
$INDP i give up, have no idea why it's doing this, but just as likely to go down same amount tomorrow
1 replies
aztecb Sep 22, 7:11 PM
$INDP wow are we about to break the current HOD
0 replies